Summit Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.25M Buy
4,983
+73
+1% +$15.7K 0.16% 66
2026
Q1
$1.07M Buy
4,910
+1
+0% +$222 0.15% 73
2025
Q4
$1.12M Buy
4,909
+51
+1% +$11.6K 0.16% 65
2025
Q3
$1.12M Buy
4,858
+1
+0% +$204 0.17% 65
2025
Q2
$902K Buy
4,857
+29
+0.6% +$5.39K 0.15% 74
2025
Q1
$1.01M Buy
4,828
+1
+0% +$194 0.18% 68
2024
Q4
$858K Buy
4,827
+1
+0% +$184 0.15% 76
2024
Q3
$953K Buy
4,826
+1
+0% +$187 0.18% 65
2024
Q2
$828K Sell
4,825
-84
-2% -$13.9K 0.17% 68
2024
Q1
$894K Buy
4,909
+2
+0% +$345 0.19% 59
2023
Q4
$761K Buy
4,907
+528
+12% +$77K 0.18% 63
2023
Q3
$653K Buy
4,379
+1
+0% +$147 0.18% 66
2023
Q2
$590K Sell
4,378
-51
-1% -$7.48K 0.16% 73
2023
Q1
$706K Buy
4,429
+102
+2% +$15.6K 0.19% 59
2022
Q4
$699K Buy
4,327
+2
+0% +$307 0.2% 63
2022
Q3
$581K Buy
4,325
+1
+0% +$143 0.19% 68
2022
Q2
$662K Sell
4,324
-135
-3% -$20.6K 0.2% 63
2022
Q1
$723K Buy
4,459
+259
+6% +$37.6K 0.21% 67
2021
Q4
$569K Buy
4,200
+337
+9% +$39.8K 0.16% 79
2021
Q3
$417K Sell
3,863
-382
-9% -$43.6K 0.13% 95
2021
Q2
$478K Buy
4,245
+392
+10% +$44.1K 0.15% 79
2021
Q1
$417K Sell
3,853
-490
-11% -$52.4K 0.14% 90
2020
Q4
$465K Buy
4,343
+509
+13% +$48.9K 0.17% 76
2020
Q3
$336K Buy
3,834
+609
+19% +$57.3K 0.14% 88
2020
Q2
$317K Buy
+3,225
New +$284K 0.14% 86
2020
Q1
Sell
-2,523
Closed -$223K 111
2019
Q4
$223K Buy
+2,523
New +$209K 0.1% 108
2019
Q1
Sell
-2,434
Closed -$224K 112
2018
Q4
$224K Buy
2,434
+13
+0.5% +$1.14K 0.13% 91
2018
Q3
$229K Buy
2,421
+12
+0.5% +$1.14K 0.11% 101
2018
Q2
$223K Buy
2,409
+11
+0.5% +$1.07K 0.11% 100
2018
Q1
$227K Buy
2,398
+7
+0.3% +$769 0.11% 98
2017
Q4
$231K Sell
2,391
-149
-6% -$14K 0.11% 100
2017
Q3
$226K Buy
+2,540
New +$193K 0.11% 98
2015
Q2
Sell
-3,988
Closed -$233K 94
2015
Q1
$233K Buy
3,988
+9
+0.2% +$544 0.16% 83
2014
Q4
$260K Buy
3,979
+7
+0.2% +$441 0.19% 76
2014
Q3
$229K Sell
3,972
-1,237
-24% -$68.7K 0.18% 75
2014
Q2
$294K Buy
5,209
+9
+0.2% +$472 0.23% 67
2014
Q1
$267K Buy
5,200
+8
+0.2% +$404 0.21% 71
2013
Q4
$274K Sell
5,192
-200
-4% -$9.83K 0.22% 67
2013
Q3
$241K Buy
5,392
+200
+4% +$8.87K 0.21% 72
2013
Q2
$215K Buy
+5,192
New +$227K 0.21% 73

Other funds holding ABBV

Summit Asset Management's ABBV Position: Q2 2026 in Review

Summit Asset Management increased its AbbVie (ABBV) stake by 1.5% in Q2 2026, buying an estimated $15.7K and bringing the position to 4,983 shares worth $1.25M. The position accounts for 0.16% of the portfolio, ranked #66.

Summit Asset Management first reported a position in ABBV in Q2 2013 and has held it in 40 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Summit Asset Management held 4,983 shares of AbbVie worth $1.25M as of Q2 2026.
  • Summit Asset Management bought 73 AbbVie shares in Q2 2026, an estimated $15.7K.
  • AbbVie made up 0.16% of Summit Asset Management's portfolio in Q2 2026, its #66 holding.
  • Summit Asset Management first reported a position in AbbVie in Q2 2013 and has held it in 40 quarters since.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Summit Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.